CINGULATE INC.(CING),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CING CINGULATE INC.

Trading 12-22 13:36:21 EST

4.21

+0.24

+6.05%

High4.24	Low3.90	Vol102.71K
Open3.93	D1 Closing3.97	Amplitude8.56%
Mkt Cap28.45M	Tradable Cap23.57M	Total Shares6.76M
T/O423.12K	T/O Rate1.83%	Tradable Shares5.60M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CING","market":"US","secType":"STK","nameCN":"CINGULATE INC.","latestPrice":4.21,"timestamp":1766428487125,"preClose":3.97,"halted":0,"volume":102707,"delay":0,"floatShares":5598200,"shares":6757070,"eps":-5.468895,"marketStatus":"Trading","change":0.24,"latestTime":"12-22 13:36:21 EST","open":3.93,"high":4.24,"low":3.9,"amount":423121.6786962,"amplitude":0.085642,"askPrice":4.25,"askSize":50,"bidPrice":4.18,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-5.468895,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1766437200000},"marketStatusCode":2,"adr":0,"listingDate":1633579200000,"exchange":"NASDAQ","adjPreClose":3.97,"preHourTrading":{"tag":"盘前","latestPrice":3.97,"preClose":3.97,"latestTime":"09:25 EST","volume":105,"amount":416.85,"timestamp":1766413500023},"postHourTrading":{"tag":"盘后","latestPrice":3.85,"preClose":3.97,"latestTime":"17:42 EST","volume":2186,"amount":8465.47,"timestamp":1766184168293},"volumeRatio":1.101009},"requestUrl":"/m/hq/s/CING","defaultTab":"news","newsList":[{"id":"2591628032","title":"BRIEF- Shane Schaffer Reinstated As CEO Of Cingulate","url":"https://stock-news.laohu8.com/highlight/detail?id=2591628032","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591628032?lang=en_us&edition=fundamental","pubTime":"2025-12-16 00:34","pubTimestamp":1765816476,"startTime":"0","endTime":"0","summary":"BRIEF- Shane Schaffer Reinstated As CEO Of CingulateDec 15  - Cingulate Inc CING.O:CINGULATE INC - SHANE SCHAFFER REINSTATED AS CEO OF CINGULATE - SEC FILINGCINGULATE INC: JOHN ROBERTS WILL NO LONGER SERVE AS EXEC CHAIRMAN BUT WILL CONTINUE TO SERVE AS CHAIRMAN OF BOARDSource text: [ID:n0001493152-25-027667]Further company coverage: CING.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nFWN3XL0XD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CING","BK4007"],"gpt_icon":0},{"id":"2591764472","title":"Cingulate Inc - Shane Schaffer Reinstated as CEO of Cingulate - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2591764472","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591764472?lang=en_us&edition=fundamental","pubTime":"2025-12-15 22:16","pubTimestamp":1765808219,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nFWN3XL0XD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CING","BK4007"],"gpt_icon":0},{"id":"2591722644","title":"Cingulate Inc: John Roberts Will No Longer Serve as Exec Chairman but Will Continue to Serve as Chairman of Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2591722644","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591722644?lang=en_us&edition=fundamental","pubTime":"2025-12-15 22:16","pubTimestamp":1765808219,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nFWN3XL0XD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CING","BK4007"],"gpt_icon":0},{"id":"2591644775","title":"Cingulate Inc. Revises CEO Compensation Terms Following Administrative Leave","url":"https://stock-news.laohu8.com/highlight/detail?id=2591644775","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591644775?lang=en_us&edition=fundamental","pubTime":"2025-12-15 22:15","pubTimestamp":1765808104,"startTime":"0","endTime":"0","summary":"Cingulate Inc. has announced changes to the employment agreement with Dr. Shane Schaffer, the company's Chief Executive Officer. Effective December 15, 2025, Dr. Schaffer's base salary has been reinstated following a period of administrative leave. The definition of \"Cause\" for termination in his agreement was revised to include any court determination that Dr. Schaffer has violated court-imposed probation and to remove the requirement that certain actions be willful. Additionally, the number of directors needed to decide on termination for cause has been reduced to a majority, excluding Dr. Schaffer. Severance terms were also adjusted: in the event of termination without cause or for good reason, Dr. Schaffer will now receive a lump sum equal to one times his base salary and annual target bonus; if termination occurs within twelve months following a change in control, the payout will be one and a half times base salary and annual target bonus.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDL82KQ5Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CING","BK4007"],"gpt_icon":0},{"id":"2589331957","title":"Cingulate Is Maintained at Buy by Ascendiant Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2589331957","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589331957?lang=en_us&edition=fundamental","pubTime":"2025-12-08 18:29","pubTimestamp":1765189740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CING/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 08, 2025 05:29 ET (10:29 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CING"],"gpt_icon":0},{"id":"2584208409","title":"Cingulate Is Maintained at Buy by Roth Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2584208409","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584208409?lang=en_us&edition=fundamental","pubTime":"2025-11-20 02:10","pubTimestamp":1763575800,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CING/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 19, 2025 13:10 ET (18:10 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CING"],"gpt_icon":0},{"id":"2584602889","title":"Cingulate price target lowered to $16 from $17 at Roth Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2584602889","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584602889?lang=en_us&edition=fundamental","pubTime":"2025-11-19 08:55","pubTimestamp":1763513707,"startTime":"0","endTime":"0","summary":"Roth Capital analyst Boobalan Pachaiyappan lowered the firm’s price target on Cingulate (CING) to $16 from $17 and keeps a Buy rating on the shares...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cingulate-price-target-lowered-to-16-from-17-at-roth-capital-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cingulate-price-target-lowered-to-16-from-17-at-roth-capital-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CING"],"gpt_icon":0},{"id":"2584796658","title":"Cingulate Inc. Signs Exclusive Commercial Supply Agreement with Bend Bio Sciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2584796658","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584796658?lang=en_us&edition=fundamental","pubTime":"2025-11-19 05:28","pubTimestamp":1763501304,"startTime":"0","endTime":"0","summary":"Cingulate Inc. announced the execution of an exclusive commercial supply agreement with Bend Bio Sciences to secure U.S. manufacturing capacity for its lead product candidate, CTx-1301. This agreement is part of Cingulate's preparation for a potential 2026 launch of CTx-1301, pending FDA approval.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cingulate Inc. published the original content used to generate this news brief via Newsfile  on November 18, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL1Gv5qw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CING","BK4007"],"gpt_icon":0},{"id":"2584644000","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2584644000","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584644000?lang=en_us&edition=fundamental","pubTime":"2025-11-17 19:00","pubTimestamp":1763377200,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·J & J Snack Fds                                 4Q      1.24        BMO","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTES","CPRT","CRDL","ANRO","ARBE","CPA","ACM","BULL","EARN","VIPS","BBWI","ZTO","AZTA","ENR","AHL","ATKR","ADIL","TGT","TCOM","BMA","CDLR","CLSD","BRBR","ALLT","CRNC","DE","CRGO","CLCO","TBBB","ARMK","AS","WMT","WB","DY","ATOS","BV","XP","CGON","POWL","ATRA","AREC","CING","NVDA","BNTC","DLB","ENTA","BZ"],"gpt_icon":1},{"id":"2583655005","title":"Cingulate Inc.’s Promising Market Position Bolstered by Strategic Partnerships and Innovative ADHD Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2583655005","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583655005?lang=en_us&edition=fundamental","pubTime":"2025-11-16 00:25","pubTimestamp":1763223929,"startTime":"0","endTime":"0","summary":"Cingulate Inc, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Naz Rahman from Maxim Group reiterated a Bu...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/cingulate-inc-s-promising-market-position-bolstered-by-strategic-partnerships-and-innovative-adhd-treatment-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/cingulate-inc-s-promising-market-position-bolstered-by-strategic-partnerships-and-innovative-adhd-treatment-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLV","LABU","BK4585","ABVC","CING","ADHD","BK4007","XBI","BK4588","BK4139","BK4581"],"gpt_icon":0},{"id":"2583980577","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2583980577","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583980577?lang=en_us&edition=fundamental","pubTime":"2025-11-14 19:00","pubTimestamp":1763118000,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Li Auto Inc. Sp ADR                               3Q       .10. ·J & J Snack Fds                                 4Q      1.24        BMO","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TGT","WB","CLSD","NTES","BNTC","BTBT","BZ","DE","ANRO","CRDL","ATRA","BBAR","CPA","CRNC","ZTO","AS","AZTA","ADIL","BBWI","BV","POWL","BNZI","CRGO","CING","ARMK","ALLT","CGON","DEFT","XP","ATKR","CDLR","ACM","ATAI","CLCO","AREC","TCOM","DLB","ATOS","LGN","AHL","DY","BMA","BRBR","ARBE","NVDA"],"gpt_icon":1},{"id":"2583598435","title":"Cingulate reports Q3 net loss ($7.3M) vs ($4.1M) last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2583598435","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583598435?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:16","pubTimestamp":1763039801,"startTime":"0","endTime":"0","summary":"As of September 30, 2025, Cingulate (CING) had approximately $6.1 million in cash and cash equivalents, a $6.1 million decrease from December 31, 2...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cingulate-reports-q3-net-loss-7-3m-vs-4-1m-last-year-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cingulate-reports-q3-net-loss-7-3m-vs-4-1m-last-year-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CING"],"gpt_icon":0},{"id":"2583598619","title":"Biopharma firm Cingulate's Q3 net loss widens, misses analyst expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2583598619","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583598619?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:09","pubTimestamp":1763039394,"startTime":"0","endTime":"0","summary":"Biopharma firm Cingulate's Q3 net loss widens, misses analyst expectationsOverviewCingulate Q3 net loss of $7.3 mln missed analyst expectationsR&D expenses rose 99.5% due to NDA submission costs for C","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nL1N3WP0JG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CING","BK4007"],"gpt_icon":0},{"id":"2583560206","title":"Cingulate Inc. posts third quarter loss of $6.0 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583560206","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583560206?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:00","pubTimestamp":1763038826,"startTime":"0","endTime":"0","summary":"Cingulate Inc. reported a net loss of $6.0 million for the third quarter of 2025, compared to a net loss of $3.3 million in the same period in 2024. For the nine months ended September 30, 2025, the net loss was $14.4 million, up from $9.4 million in the prior year period. Research and development expenses for the quarter were $2.8 million, and general and administrative expenses were $3.1 million, both higher than the previous year. As of September 30, 2025, cash and cash equivalents totaled $6.1 million, with total assets at $10.5 million and stockholders' equity at $3.5 million. During the period, the FDA accepted Cingulate's New Drug Application for CTx-1301, with a Prescription Drug User Fee Act  date set for May 31, 2026. The company also completed a $6.6 million financing transaction through a non-convertible, unsecured promissory note.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL9J4DcZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","BK4007","CING","LU2210149790.SGD","IE00B64PRP62.GBP","LU0314104364.USD","BK4588","LU2210150020.SGD","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4112","NDAQ","BK4585","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2582893413","title":"Cingulate Inc. Files Initial Statement of Beneficial Ownership for Chief Commercial Officer Bryan Wade Downey","url":"https://stock-news.laohu8.com/highlight/detail?id=2582893413","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582893413?lang=en_us&edition=fundamental","pubTime":"2025-11-11 07:00","pubTimestamp":1762815648,"startTime":"0","endTime":"0","summary":"Cingulate Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing lists Bryan Wade Downey as the beneficial owner, who serves as the Chief Commercial Officer of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cingulate Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 10, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL64bYF8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CING","BK4007"],"gpt_icon":0},{"id":"2582879799","title":"Cingulate Inc. Appoints Bryan Downey as Chief Commercial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2582879799","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582879799?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:03","pubTimestamp":1762779826,"startTime":"0","endTime":"0","summary":"Cingulate Inc. announced the appointment of Bryan Downey as Chief Commercial Officer. This leadership change comes as the company prepares for the potential commercialization of its lead product, CTx-1301, pending FDA approval.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cingulate Inc. published the original content used to generate this news brief via GlobeNewswire  on November 10, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDLbHzqLq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4007","LU2095319765.USD","LU2210150020.SGD","CING","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4585","BK4588","NDAQ","LU0314104364.USD","IE00B64PRP62.GBP","BK4112","LU2210149790.SGD"],"gpt_icon":0},{"id":"2582879286","title":"Press Release: Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301","url":"https://stock-news.laohu8.com/highlight/detail?id=2582879286","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582879286?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:00","pubTimestamp":1762779600,"startTime":"0","endTime":"0","summary":"Appointment builds on recent FDA acceptance of New Drug Application for review and advances Cingulate's transition toward commercialization pending FDA approval. Company also strengthens its cash position by completing a $6 million financing. Cingulate also announced it has completed a $6 million financing transaction, further strengthening its balance sheet and extending its cash runway into the second quarter of 2026, as the company prepares for commercialization, subject to FDA approval.\"Cingulate is at a pivotal moment as we prepare to bring CTx-1301 to market,\" said Bryan Downey, Chief Commercial Officer. \"The potential to deliver rapid onset and entire active-day ADHD symptom control in one daily dose is a substantial differentiator from medications currently available. With our new drug application now accepted for review, we're working closely with our partners at Indegene to establish the commercial infrastructure, market access execution, and launch readiness that will positi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TQQQ","TSYW.SI","SQQQ","PSQ","CING","BK4139","BK4585","NVIW.SI","BK4604","BK4007","QID",".IXIC","03160","ADHD","MNQmain","BK4588","BK4555","USJW.SI","ABVC","USAW.SI","BK4099","QLD","TM","NQmain"],"gpt_icon":1},{"id":"2578951980","title":"BRIEF-Cingulate Presents Positive Phase 3 Results for CTx-1301","url":"https://stock-news.laohu8.com/highlight/detail?id=2578951980","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578951980?lang=en_us&edition=fundamental","pubTime":"2025-10-28 20:22","pubTimestamp":1761654141,"startTime":"0","endTime":"0","summary":"BRIEF-Cingulate Presents Positive Phase 3 Results for CTx-1301Oct 28 (Reuters) - Cingulate Inc CING.O:CINGULATE PRESENTS POSITIVE PHASE 3 RESULTS FOR CTX-1301 DEMONSTRATING STATISTICALLY SIGNIFICANT E","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251028:nTUABXQ6SB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CINGW","CING","BK4007"],"gpt_icon":0},{"id":"2578959073","title":"Cingulate Presents Positive Phase 3 Results for CTx-1301 Demonstrating Statistically Significant Efficacy and Entire Active-Day Symptom Control","url":"https://stock-news.laohu8.com/highlight/detail?id=2578959073","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578959073?lang=en_us&edition=fundamental","pubTime":"2025-10-28 20:00","pubTimestamp":1761652800,"startTime":"0","endTime":"0","summary":"Once-daily formulation of dexmethylphenidate achieved primary endpoint (p < 0.001) with consistent symptom relief up to 12 hours post-doseKANSAS CITY, Kan., Oct.  28, 2025  (GLOBE NEWSWIRE) -- Cingula","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/28/3175360/0/en/Cingulate-Presents-Positive-Phase-3-Results-for-CTx-1301-Demonstrating-Statistically-Significant-Efficacy-and-Entire-Active-Day-Symptom-Control.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CING"],"gpt_icon":0},{"id":"2577531411","title":"Cingulate’s Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2577531411","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577531411?lang=en_us&edition=fundamental","pubTime":"2025-10-24 04:45","pubTimestamp":1761252300,"startTime":"0","endTime":"0","summary":"Presentation by ADHD expert Dr. Ann Childress to highlight Phase 3 findings supporting the potential for true, entire active-day symptom controlKANSAS CITY, Kan., Oct.  23, 2025  (GLOBE NEWSWIRE) -- C","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/23/3172521/0/en/Cingulate-s-Lead-ADHD-Candidate-CTx-1301-Selected-for-Podium-Presentation-at-AACAP-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ABVC","ADHD","CING","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cingulate.com","stockEarnings":[{"period":"1week","weight":-0.1059},{"period":"1month","weight":0.1608},{"period":"3month","weight":0.1215},{"period":"6month","weight":-0.0411},{"period":"1year","weight":-0.0317},{"period":"ytd","weight":-0.1947}],"compareEarnings":[{"period":"1week","weight":-0.0017},{"period":"1month","weight":0.0271},{"period":"3month","weight":0.0254},{"period":"6month","weight":0.1452},{"period":"1year","weight":0.1612},{"period":"ytd","weight":0.1613}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.260215},{"month":2,"riseRate":0.25,"avgChangeRate":-0.006109},{"month":3,"riseRate":0.5,"avgChangeRate":-0.052642},{"month":4,"riseRate":0.25,"avgChangeRate":-0.067094},{"month":5,"riseRate":0,"avgChangeRate":-0.197282},{"month":6,"riseRate":0.75,"avgChangeRate":-0.035954},{"month":7,"riseRate":0.5,"avgChangeRate":-0.055289},{"month":8,"riseRate":0.75,"avgChangeRate":0.301563},{"month":9,"riseRate":0.25,"avgChangeRate":-0.156522},{"month":10,"riseRate":0.25,"avgChangeRate":-0.153936},{"month":11,"riseRate":0.25,"avgChangeRate":-0.072096},{"month":12,"riseRate":1,"avgChangeRate":0.105632}],"exchange":"NASDAQ","name":"CINGULATE INC.","nameEN":"CINGULATE INC."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CINGULATE INC.(CING),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CINGULATE INC.(CING) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CINGULATE INC.,CING,CINGULATE INC.股票,CINGULATE INC.股票老虎,CINGULATE INC.股票老虎国际,CINGULATE INC.行情,CINGULATE INC.股票行情,CINGULATE INC.股价,CINGULATE INC.股市,CINGULATE INC.股票价格,CINGULATE INC.股票交易,CINGULATE INC.股票购买,CINGULATE INC.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CINGULATE INC.(CING),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CINGULATE INC.(CING) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction